Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria

Leuk Lymphoma. 2019 Feb;60(2):326-333. doi: 10.1080/10428194.2018.1482541. Epub 2018 Jul 3.


Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist. Sixty-five patients were retrospectively included: all underwent baseline 18F-FDG-PET/CT, 56 interim PET/CT (iPET/CT) and 54 end of treatment PET/CT (eotPET/CT) after chemotherapy. Interim and eotPET/CT results were visually interpreted according to the criteria of the IHP and Deauville-five-point-scale. Results were correlated with PFS and OS to assess and to compare the predictive value of iPET and eotPET according to each criterion. All baseline PET/CT showed increased 18F-FDG uptake in nodal and extranodal lesions. The median PFS and OS were 44.6 and 48.2 months with 3-year and 5-year PFS of 76% and 62% and 3-year and 5-year OS of 71% and 57%, respectively. EotPET/CT results using DC and IHP significantly correlate with OS and PFS; while iPET/CT did not correlated with OS and PFS.

Keywords: Burkitt’s lymphoma; Deauville criteria; International Harmonization Project; PET/CT.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers
  • Burkitt Lymphoma / diagnosis*
  • Burkitt Lymphoma / metabolism*
  • Burkitt Lymphoma / mortality
  • Burkitt Lymphoma / therapy
  • Disease Management
  • Energy Metabolism*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography*
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult


  • Biomarkers
  • Fluorodeoxyglucose F18